Group 1 - Sangfor Technologies (01530) shares surged over 18% to a new historical high of HKD 35.62, with a trading volume of HKD 3.343 billion [1] - On September 4, the CDE announced the approval of Sangfor's SA102-CAR-T injection for clinical use in treating relapsed refractory multiple myeloma [1] - SA102 is the first CS1/BCMA dual-target CAR-T product globally to obtain clinical safety and efficacy data, developed by Sian Medical [1] Group 2 - In December 2023, Sangfor signed a patent licensing agreement with Sian Medical, granting exclusive rights for the development, registration, production, and commercialization of SA102 in Greater China [1] - Pfizer announced that SSGJ-707 is set to initiate global Phase III trials for non-small cell lung cancer by the end of 2025, with further exploration in other tumor types [1] - According to CMB International, SSGJ-707 has the potential to become a blockbuster drug, and its global clinical development is expected to be a significant catalyst for the company's profitability [1]
三生制药尾盘涨超18%创新高 双靶点CAR-T获批临床 辉瑞积极推动707研发